Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 2,544 | 2,260 | 2,137 | 2,524 | 2,630 |
| Cost of Goods | 2,166 | 1,892 | 1,794 | 2,215 | 2,304 |
| Gross Profit | 378 | 368 | 344 | 309 | 327 |
| Operating Expenses | 1,246 | 1,872 | 1,756 | 940 | 1,968 |
| Operating Income | -703 | -611 | -618 | -416 | -1,338 |
| Interest Expense | 21 | 30 | 24 | 34 | 35 |
| Other Income | 14 | 25 | 19 | 28 | 29 |
| Pre-tax Income | -709 | -616 | -623 | -422 | -1,344 |
| Income Tax | N/A | N/A | N/A | -74 | 2 |
| Net Income Continuous | -709 | -616 | -623 | -348 | -1,345 |
| Net Income | $-709 | $-616 | $-623 | $-348 | $-1,345 |
| EPS Basic Total Ops | -0.40 | -0.34 | -0.04 | 0.55 | -0.75 |
| EPS Basic Continuous Ops | -0.39 | -0.34 | -0.03 | 0.55 | -0.75 |
| EPS Diluted Total Ops | -0.40 | -0.34 | -0.04 | 0.55 | -0.75 |
| EPS Diluted Continuous Ops | -0.39 | -0.34 | -0.03 | 0.55 | -0.75 |
| EPS Diluted Before Non-Recurring Items | -0.39 | -0.34 | -0.03 | N/A | -0.20 |
| EBITDA(a) | $-638 | $-540 | $-555 | $-339 | $-1,254 |